Australia's Noxopharm surges most in near 2 years after U.S FDA grant for cancer drug

Noxopharm

22/03/2022 01:03

** Shares of Noxopharm Ltd  NOX.AX  climb as much as 23.4%
to A$0.395, the biggest intraday pct gain since May 19, 2020 
    ** The clinical drug developer says U.S. Food and Drug
Administration has granted Orphan Drug Designation for its
oncology drug Veyonda  urn:newsml:reuters.com:*:nASM0004EU
    ** Says that drug is used in the treatment of soft tissue
sarcoma 
    ** Shares hit highest since Feb 22
    ** About 589,015 shares change hands, 2.6 times compared
with the 30-day average volume of 222,489 shares    
    ** Stock down 18% this year, as of last close

 (Reporting by Archishma Iyer)
 ((Archishma.Iyer@thomsonreuters.com;))